Valuation: Compass Therapeutics, Inc.

Market Cap 42Cr 37Cr 34Cr 31Cr 59Cr 4TCr 60Cr 406.72Cr 158.03Cr 1.96TCr 156.9Cr 153.46Cr 6.8TCr P/E 2026 *
-5.32x
P/E 2027 * -4.99x
Enterprise Value 27Cr 23Cr 22Cr 20Cr 38Cr 2.56TCr 39Cr 260.7Cr 101.29Cr 1.25TCr 100.57Cr 98Cr 4.36TCr EV / Sales 2026 *
-130x
EV / Sales 2027 * 11.3x
Free-Float
87.55%
Yield 2026 *
-
Yield 2027 * -
1 day+0.86%
1 week+7.34%
Current month+6.85%
1 month+15.84%
3 months-56.67%
6 months-54.74%
Current year-56.42%
1 week 2.15
Extreme 2.15
2.35
1 month 1.88
Extreme 1.88
2.35
Current year 1.61
Extreme 1.61
6.88
1 year 1.61
Extreme 1.61
6.88
3 years 0.76
Extreme 0.765
6.88
5 years 0.76
Extreme 0.765
6.88
10 years 0.76
Extreme 0.765
11
Manager TitleAgeSince
Chief Executive Officer 65 28/05/2024
Director of Finance/CFO 54 09/12/2024
Chief Tech/Sci/R&D Officer 50 01/01/2026
Director TitleAgeSince
Director/Board Member 65 01/01/2014
Director/Board Member 64 01/01/2015
Chairman 61 01/01/2015
Date Insider Type Main position Quantity % Market Cap.
29/04Buy

Controller/Auditor

15,000 0.0083%
29/04Buy

General Counsel

25,000 0.0139%
08/02Tax

Chief Executive Officer

36,687 0.0206%
Change 5-day change 1-year change 3-year change Capi.($)
+0.86%+7.34%-11.70%-21.21% 42Cr
-1.53%-1.43%+71.67%+129.70% 5.77TCr
-2.45%-7.32%+65.23%+83.15% 5.27TCr
+3.27%+8.91%+21.21%+471.23% 2.45TCr
-0.81%+0.52%-15.01%-12.47% 2.38TCr
-3.05%+3.06%+42.36%-5.66% 1.93TCr
-0.24%+5.11%+38.76%-25.95% 1.78TCr
+2.34%+14.18%+220.96%+380.99% 1.73TCr
-6.73%+9.90%+36.04% - 1.53TCr
-1.70%+3.98%+28.96%+194.23% 1.43TCr
Average -1.00%+5.27%+49.85%+132.67% 2.43TCr
Weighted average by Cap. -1.26%+2.71%+57.67%+139.96%

Financials

2026 *2027 *
Net sales -20.57L -18.04L -16.66L -15.39L -29.18L -20Cr -29.76L -2Cr -77.81L -9.64Cr -77.25L -75.56L -33Cr 2.53Cr 2.22Cr 2.05Cr 1.89Cr 3.58Cr 241.95Cr 3.66Cr 25Cr 9.56Cr 118.4Cr 9.49Cr 9.28Cr 411.03Cr
Net income -8.24Cr -7.23Cr -6.68Cr -6.17Cr -12Cr -789.35Cr -12Cr -80Cr -31Cr -386.28Cr -31Cr -30Cr -1.34TCr -8.96Cr -7.86Cr -7.25Cr -6.7Cr -13Cr -857.63Cr -13Cr -87Cr -34Cr -419.69Cr -34Cr -33Cr -1.46TCr
Net Debt -15Cr -13Cr -12Cr -11Cr -21Cr -1.44TCr -22Cr -146.02Cr -57Cr -702.86Cr -56Cr -55Cr -2.44TCr -13Cr -12Cr -11Cr -9.88Cr -19Cr -1.26TCr -19Cr -128.5Cr -50Cr -618.52Cr -50Cr -48Cr -2.15TCr
Logo Compass Therapeutics, Inc.
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, tovecimig, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor, and its ligand PD-L1, two validated immune-oncology targets.
Employees
39
Date Price Change Volume
09/26/09 $2.340 +0.86% 38,80,784
07/26/07 $2.320 +1.31% 32,12,752
06/26/06 $2.290 +0.88% 24,81,789
02/26/02 $2.270 +4.13% 29,39,846
01/26/01 $2.180 -0.46% 23,79,040
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
2.320USD
Average target price
8.500USD
Spread / Average Target
+266.38%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CMPX Stock